| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
7,3',4'-Tri-O-methyleriodictyol targets multiple biological pathways. It exhibits antimutagenic activity by inhibiting the furylfuramide-induced SOS response, suggesting interaction with DNA repair or mutagenesis pathways. The compound also shows antibacterial activity against Mycobacterium tuberculosis, antioxidant properties, antitumor activity, and antiprotozoal activity. As a methylated flavonoid from Pogostemon cablin, it may interact with various cellular targets involved in oxidative stress, inflammation, and microbial infection.
|
|---|---|
| ln Vitro |
In vitro, 7,3',4'-Tri-O-methyleriodictyol exhibits antimutagenic activity by inhibiting furylfuramide-induced SOS response. The compound has antibacterial activity against Mycobacterium tuberculosis infection. It also demonstrates antioxidant properties, antitumor activity, and antiprotozoal activity. These diverse activities suggest the compound has multiple mechanisms of action and may be a valuable lead compound for various therapeutic applications. However, detailed IC₅₀ values are not extensively published.
|
| ln Vivo |
In vivo activity data for 7,3',4'-Tri-O-methyleriodictyol are limited in the published literature. The compound has been primarily characterized through in vitro studies. Given its antibacterial, antioxidant, antitumor, and antimutagenic activities, potential in vivo studies could include models of bacterial infection, cancer, or mutagenesis. However, such studies have not been extensively reported. Further research is needed to evaluate its in vivo efficacy.
|
| Enzyme Assay |
In vitro antimutagenic assays for 7,3',4'-Tri-O-methyleriodictyol typically involve evaluation of the SOS response induced by furylfuramide. Bacterial reporter systems (e.g., Salmonella typhimurium with SOS-inducible reporters) are used to measure SOS induction in the presence of the compound. Antibacterial activity is assessed using broth microdilution or disc diffusion methods against Mycobacterium tuberculosis and other bacterial strains. Antioxidant activity is evaluated using DPPH or ABTS radical scavenging assays.
|
| Cell Assay |
In vitro cellular assays for 7,3',4'-Tri-O-methyleriodictyol could include evaluation of antitumor activity using cancer cell lines. Cells are treated with the compound and cell viability is assessed using MTT or similar assays. For antiprotozoal activity, parasites are cultured and treated with the compound. Antibacterial activity against Mycobacterium tuberculosis can be evaluated in infected macrophage cultures. The compound is purified from Pogostemon cablin.
|
| Animal Protocol |
In vivo animal experiments for 7,3',4'-Tri-O-methyleriodictyol have not been extensively reported. Based on its antibacterial, antioxidant, and antitumor activities, potential studies could include rodent models of bacterial infection, cancer, or oxidative stress. However, such studies have not been published for this specific compound to date.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7,3',4'-Tri-O-methyleriodictyol are characteristic of methylated flavonoids. The compound has a molecular weight of 330.33 g/mol and molecular formula C₁₈H₁₈O₆. As a lipophilic methylated flavonoid, it is expected to have good oral absorption and tissue distribution. The compound is purified from Pogostemon cablin with purity 98.5%. Storage: powder at -20°C for 3 years or 4°C for 2 years.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 7,3',4'-Tri-O-methyleriodictyol is not extensively documented. As a flavonoid from Pogostemon cablin with antimutagenic activity, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
According to reports, Pogostemon cablin contains 7,3',4'-tri-O-methylsuccinol, and there is relevant data available.
7,3',4'-Tri-O-methyleriodictyol (CAS# 70987-96-1, molecular formula C₁₈H₁₈O₆, molecular weight 330.33) is a flavonoid from Pogostemon cablin with antimutagenic, antibacterial, antioxidant, antitumor, and antiprotozoal activities. It inhibits the furylfuramide-induced SOS response. No clinical trials or regulatory approvals have been identified. Purity: 98.5%. |
| Molecular Formula |
C18H18O6
|
|---|---|
| Molecular Weight |
330.331925868988
|
| Exact Mass |
330.11
|
| CAS # |
70987-96-1
|
| PubChem CID |
14078482
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.124
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
441
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2C=C(C=C(C=2C(C[C@H]1C1C=CC(=C(C=1)OC)OC)=O)O)OC
|
| InChi Key |
MRFOCZPULZWYTJ-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C18H18O6/c1-21-11-7-12(19)18-13(20)9-15(24-17(18)8-11)10-4-5-14(22-2)16(6-10)23-3/h4-8,15,19H,9H2,1-3H3/t15-/m0/s1
|
| Chemical Name |
(2S)-2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0273 mL | 15.1364 mL | 30.2728 mL | |
| 5 mM | 0.6055 mL | 3.0273 mL | 6.0546 mL | |
| 10 mM | 0.3027 mL | 1.5136 mL | 3.0273 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
